CA3101612A1 - Composition and method of treating cancer associated with egfr mutation - Google Patents

Composition and method of treating cancer associated with egfr mutation Download PDF

Info

Publication number
CA3101612A1
CA3101612A1 CA3101612A CA3101612A CA3101612A1 CA 3101612 A1 CA3101612 A1 CA 3101612A1 CA 3101612 A CA3101612 A CA 3101612A CA 3101612 A CA3101612 A CA 3101612A CA 3101612 A1 CA3101612 A1 CA 3101612A1
Authority
CA
Canada
Prior art keywords
plinabulin
cancer
osimertinib
tumor
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3101612A
Other languages
English (en)
French (fr)
Inventor
Lan Huang
George Kenneth Lloyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Pharmaceuticals Inc
Original Assignee
BeyondSpring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeyondSpring Pharmaceuticals Inc filed Critical BeyondSpring Pharmaceuticals Inc
Publication of CA3101612A1 publication Critical patent/CA3101612A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3101612A 2018-06-01 2019-05-30 Composition and method of treating cancer associated with egfr mutation Pending CA3101612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679619P 2018-06-01 2018-06-01
US62/679,619 2018-06-01
PCT/US2019/034726 WO2019232257A1 (en) 2018-06-01 2019-05-30 Composition and method of treating cancer associated with egfr mutation

Publications (1)

Publication Number Publication Date
CA3101612A1 true CA3101612A1 (en) 2019-12-05

Family

ID=68696755

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3101612A Pending CA3101612A1 (en) 2018-06-01 2019-05-30 Composition and method of treating cancer associated with egfr mutation

Country Status (11)

Country Link
US (2) US20210161888A1 (cg-RX-API-DMAC7.html)
EP (1) EP3801524B1 (cg-RX-API-DMAC7.html)
JP (1) JP7500438B2 (cg-RX-API-DMAC7.html)
KR (1) KR102790127B1 (cg-RX-API-DMAC7.html)
CN (1) CN112543636B (cg-RX-API-DMAC7.html)
AU (1) AU2019278886B2 (cg-RX-API-DMAC7.html)
CA (1) CA3101612A1 (cg-RX-API-DMAC7.html)
DK (1) DK3801524T3 (cg-RX-API-DMAC7.html)
ES (1) ES3060133T3 (cg-RX-API-DMAC7.html)
MX (1) MX420412B (cg-RX-API-DMAC7.html)
WO (1) WO2019232257A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CN109475524A (zh) 2016-06-06 2019-03-15 万春药业公司 用于减少中性粒细胞减少症的组合物和方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
CN121311228A (zh) * 2023-06-02 2026-01-09 万春药业公司 肿瘤联合治疗和使用方法
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302721B2 (en) * 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
EA201200486A1 (ru) * 2009-09-15 2012-08-30 Серулин Фарма Инк. Лечение онкологических заболеваний
SG11201505896YA (en) * 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
MX394865B (es) * 2015-02-12 2025-03-24 Beyondspring Pharmaceuticals Inc Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
HK1249052A1 (zh) * 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
BR112019018880A2 (pt) * 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals, Inc. composições de plinabulina e seu uso

Also Published As

Publication number Publication date
KR20210015875A (ko) 2021-02-10
AU2019278886B2 (en) 2025-03-20
JP2021525768A (ja) 2021-09-27
JP7500438B2 (ja) 2024-06-17
US20210161888A1 (en) 2021-06-03
DK3801524T3 (da) 2026-02-02
MX420412B (es) 2025-02-10
WO2019232257A1 (en) 2019-12-05
AU2019278886A1 (en) 2020-12-24
CN112543636A (zh) 2021-03-23
MX2020012799A (es) 2021-03-25
KR102790127B1 (ko) 2025-04-03
ES3060133T3 (en) 2026-03-25
EP3801524B1 (en) 2025-11-05
EP3801524A4 (en) 2022-03-02
US20250375440A1 (en) 2025-12-11
EP3801524A1 (en) 2021-04-14
CN112543636B (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
US20250375440A1 (en) Composition and method of treating cancer associated with egfr mutation
US11376239B2 (en) Pharmaceutical combinations
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
EP3010505A1 (en) Pharmaceutical combinations
US9446043B2 (en) Pharmaceutical combinations
CN105764510A (zh) H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途
EP4203963B1 (en) Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma
KR20210084442A (ko) 포도막 흑색종 치료를 위한 병용 요법
KR20160086962A (ko) 삼중 음성 유방 암 치료를 위해 카보플라틴과 병용된 벨리파리브
WO2024249155A1 (en) Oncology combination therapy and methods of use
HK40038993A (en) Composition and method of treating cancer associated with egfr mutation
US20240307392A1 (en) Erk1/2 and egfr inhibitors combination therapy
JP2009108058A (ja) 抗リンパ腫組成物および方法
KR102739607B1 (ko) 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물
CN115120596A (zh) 一种喹唑啉化合物及药物组合物的应用
HK1215789B (en) Pharmaceutical combinations

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240529

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20240703

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250123

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250220

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250507

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250507

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250625

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251024

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251218

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260409

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260409